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Abstract
Background: Although endothelial progenitor cells (EPCs) contribute to wound repair by promoting neovascularization,
the mechanism of EPC-mediated wound healing remains poorly understood due to the lack of pivotal molecular targets
of dermal wound repair.
Methods and Results: We found that genetic targeting of the Lnk gene in EPCs dramatically enhances the
vasculogenic potential including cell proliferation, migration, and tubule-like formation as well as accelerates
in vivo wound healing, with a reduction in fibrotic tissue and improved neovascularization via significant
suppression of inflammatory cell recruitment. When injected into wound sites, Lnk-/- EPCs gave rise to a
significant number of new vessels, with remarkably increased survival of transplanted cells and decreased
recruitment of cytotoxic T cells, macrophages, and neutrophils, but caused activation of fibroblasts in the
wound-remodeling phase. Notably, in a mouse model of type I diabetes, transplanted Lnk-/- EPCs induced
significantly better wound healing than Lnk+/+ EPCs did.
Conclusions: The specific targeting of Lnk may be a promising EPC-based therapeutic strategy for dermal
wound healing via improvement of neovascularization but inhibition of excessive inflammation as well as
activation of myofibroblasts during dermal tissue remodeling.
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Background
Wound repair is a complex but well-organized biological
process that requires the coordinated action of various
cell types and multiple signaling cascades [1, 2]. The
process consists of three phases: inflammation; tissue
formation including proliferation, angiogenesis, and
granulation; and tissue remodeling [1]. In the inflamma-
tion phase, leukocytes including neutrophils and macro-
phages are recruited to the wound site to eliminate
some pathogens and cell debris. In the phase of new
tissue formation, several types of cells migrate and pro-
liferate. Keratinocytes migrate to the wound site, and
engrafted endothelial cells (ECs) or endothelial progeni-
tor cells (EPCs) form new blood vessels. Fibroblasts also
migrate from adjacent tissues and produce the extracel-
lular matrix (ECM). In the tissue-remodeling phase, the
ECM is remodeled by fibroblasts, and myofibroblasts
play a role in connective tissue compaction and wound
contraction [3, 4]. In several pathological conditions
such as diabetes and chronic diseases, impairment of
these well-ordered healing processes leads to a delay or
overhealing of the wound, resulting in a functional dis-
order, pain, infection, or fibrosis. To address these
problems, several researchers have suggested possible
strategies to make wounds more regenerative than scar
forming, e.g., by applying small molecules, biomimetic
scaffolds, gene therapy, electrical manipulation, or a
stem/progenitor cell-based therapy [3, 5–7].
EPCs are a promising cell source for treatment of is-
chemic diseases. Since EPCs were isolated from adult
peripheral blood [8], they have been found to migrate to
the injury site and contribute to new-vessel formation as
well as to play a pivotal role in vascular maintenance [9].
Although a transplant of EPCs into an ischemic tissue
dramatically enhances the tissue repair process, patho-
logical conditions, including inflammation, ischemia,
and nutrient deficiency, lower the efficacy of engraft-
ment and decrease survival rates of EPCs in injured tis-
sue. To enhance the therapeutic efficacy, several studies
describe key strategies where molecular targeting of
EPCs facilitates their functionality and therapeutic ef-
fects at an injury site [6, 10, 11]. For example, transfer of
the manganese superoxide dismutase gene into EPCs
increases wound healing in a mouse model of type 2
diabetes [10], and modulation of the CCL5–CCR5 inter-
action enhances wound tissue repair through recruit-
ment of EPCs [6]. In addition, a CXCR4 antagonist,
AMD 3100, promotes wound healing by mobilizing bone
marrow (BM)-derived EPCs to an injury site [11]. Never-
theless, the mechanism of EPC-mediated wound healing
remains poorly understood due to the lack of key mo-
lecular targets of dermal wound repair.
Lnk adaptor protein (SH2B3) is a member of the
SH2B family of adaptor proteins, which are implicated
in regulation and modulation of various cell signaling
pathways [12]. Lnk participates in the major signaling
pathways, including those related to interleukin (IL)-3,
stem cell factor (SCF)/c-Kit, thrombopoietin (TPO)/
myeloproliferative leukemia protein (MPL), erythro-
poietin (EPO)/EPO receptor (EPOR), platelet-derived
growth factor (PDGF)/PDGF receptor (PDGFR), tumor
necrosis factor (TNF), and integrins [12]. In addition, Lnk
affects several effector targets, such as phosphoinositol-
4,5-bisphosphate 3-kinase (PI3K)/Akt, p38 mitogen-
activated protein kinases (MAPK), extracellular signal-
regulated kinases (ERK1/2), and Janus kinase 2 (JAK2)/
signal transducer and activator of transcription 3 (STAT3),
and STAT5 [12]. Our previous studies showed that Lnk
deficiency enhances the capacity for cell growth, endothe-
lial commitment, mobilization, and recruitment of EPCs
[13]. Moreover, selective downregulation of Lnk in EPCs
promotes vascular repair and neovascularization in a mur-
ine model of hindlimb ischemia through regulation of the
JAK2/STAT3 axis [14].
In the present study, our aim was to test whether Lnk-
deficient EPCs promote wound healing through aug-
mentation of EPC bioactivities and neovascularization
with activation of myofibroblasts as well as suppression
of inflammatory cell recruitment at wound sites in
wound-healing models and in a murine model of type 1
diabetes. This report shows that the specific targeting of
Lnk may be an effective EPC-based therapeutic strategy
for promotion of dermal wound healing.
Methods
Animals
The Lnk-/- mice were generated as previously reported
[15]. Experiments were performed on 8-week-old male
C57BL/6 mice (Biogenomics, Seoul, Korea) and Lnk-/-
mice maintained in a 12-hour light/dark cycle in accord-
ance with the regulations of Pusan National University.
The protocols were approved by the Institutional Animal
Care and Use Committee of Pusan National University
School of Medicine, on the basis of the Guide for the
Care and Use of Laboratory Animals.
Murine BM-derived EPC culture
Isolation of BM-derived EPCs was performed as previ-
ously reported [13]. BM mononuclear cells (MNCs) iso-
lated from tibia and femur of wild-type and Lnk-/- mice
were plated in cell culture dishes coated with 1 % gelatin
(Sigma-Aldrich, St. Louis, MO, USA) at the density of
5 × 105/cm2 and were cultured with endothelial basal
medium 2 (EBM-2; Lonza, Walkersville, MD, USA) sup-
plemented with 5 % fetal bovine serum (FBS; Lonza) to
obtain the EPC-enriched population. The cells were
placed in a humidified incubator at 37 °C and 5 % CO2.
After 4 days, nonadherent cells were discarded, and a
Lee et al. Stem Cell Research & Therapy  (2016) 7:158 Page 2 of 12
fresh culture medium was added. Cultures were main-
tained for another 3 days to obtain the putative EPCs.
The murine model of streptozotocin-induced diabetes
To induce diabetes, a single high dose of streptozotocin
(STZ; 225 mg/kg; Sigma-Aldrich) was intraperitoneally
injected into C57BL/6 mice (fasted for 16 h beforehand,
body weight 20–23 g). Every week after STZ administra-
tion, serum glucose levels were measured using an
Accu-Check Advantage glucometer (Roche, Indianapolis,
IN, USA) during nonfasting status. Mice with a plasma
glucose level >200 mg/dl at 3 weeks after injection were
regarded as having STZ-induced diabetes [16].
The wound-healing model
The excisional wound model was generated as described
previously [17]. In brief, after shaving and cleaning with
70 % ethanol, the dorsal skin of wild-type or Lnk-/- mice
(n = 5 per group) was picked up at the midline and two
layers of skin were perforated with a sterile disposable
biopsy punch (4 mm diameter; Miltex, York, PA, USA),
generating one wound on each side of the midline. After
establishing the excisional wound model, the process of
wound healing was observed for 10 days. In EPC trans-
plantation experiments, after establishing the excisional
wound model, wild-type or Lnk-/- EPCs (105 cells) in
80 μl of PBS or 80 μl of PBS alone were homogeneously
administered into the subcutaneous tissue around the
wound defect in normal mice or in mice with STZ-
induced diabetes (n = 5 per group). Each wound site was
digitally photographed at the indicated time points after
injury, and wound areas were determined by tracing the
wound margins using the Image J software (http://
rsbweb.nih.gov/ij/). The wound area at each time point
was calculated as a percent area of the original wound.
Histological and immunohistological analysis
The wounds were excised with the surrounding tissue.
The tissue samples were fixed with 4 % paraformalde-
hyde in PBS at 4 °C for 24 h and embedded in paraffin
to prepare histological or immunohistological slides. For
histological analysis, tissue slices were stained with
hematoxylin and eosin (H&E) or Masson’s trichrome
dye. For immunohistological analysis, the slices were in-
cubated with anti-CD31, proliferating cell nuclear anti-
gen (PCNA), cleaved caspase 3, alpha-smooth muscle
actin, and vimentin antibodies (all from Santa Cruz
Biotechnology, Dallas, TX, USA) and followed by in-
cubation with Alexa Fluor 488- or 594-conjugated
secondary antibodies (Thermo Fisher Scientific, Waltham,
MA, USA). Nuclei were stained with 4′,6-diamidino-2-
phenylindole (Sigma-Aldrich). Immunostained slides were
examined under confocal microscopy (Olympus, Tokyo,
Japan). Each experiment was repeated at least three times.
Flow cytometric analysis
To verify recruitment of the EPC population or leuko-
cytes, wound tissues were harvested and digested with
0.1 % type II collagenase (Sigma-Aldrich) after postoper-
ative day 3 or 7. EPCs or single cells derived from
wound tissues were subjected to flow cytometric analysis
using anti-Sca-1, anti-c-Kit, anti-Flk-1, anti-CD34, anti-
CD3, anti-CD8, anti-CD11, and anti-CD45 antibodies
(all from BD, San Jose, CA, USA). Flow cytometry was
performed using a fluorescence-activated cell sorter
(FACS; BD). Histograms represent the cell number (y-
axis) versus the fluorescence intensity (x-axis, log scale).
FACS gating was performed using cells stained with
isotype-matched IgG as a negative control. For each
antibody, the proportion of positively stained cells was
determined by comparison with isotype-matched control
cells. The percentage of positively stained cells is indi-
cated by the positive peaks. Red lines indicate cells
stained with each antibody, and black lines indicate the
negative control cells. Each experiment was repeated at
least three times.
The cell proliferation assay
Cell proliferation was assessed using the BrdU Cell
Proliferation Assay Kit (Cell Signaling Technology,
Beverly, MA, USA) or Ez-CYTOX Kit (Daeil Biotech,
Suwon, South Korea) according to the manufacturer’s
instructions. Each experiment was repeated at least
three times.
Tubule-like formation assay
To assess tubule-like formation capacity of EPCs, a
Matrigel tube formation assay was performed. Matrigel
(BD) was added to 96-well plates and incubated at 37 °C.
Cells (104/well) were seeded in Matrigel-coated plates
and incubated for 6 h at 37 °C and 5 % CO2. The cells
were monitored by phase contrast microscopy (Olympus).
Each experiment was repeated at least three times.
The migration assay
Cells were plated in 6-well plates and grown until con-
fluence and then the monolayer was wounded with a cell
scraper. The detached cells were removed by gentle
washing with the medium. Cells were incubated for 24 h
at 37 °C and 5 % CO2 and examined under a microscope
(Olympus) equipped with a × 40 objective lens. Each ex-
periment was repeated at least three times.
Statistical analysis
All data are expressed as mean ± SEM. One-way analysis
of variance was used followed by Tukey’s post hoc test
for multiple comparisons, or a Student’s t test was used
for paired comparisons. A p value < 0.05 was considered
to indicate a significant difference.
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Results
Improved wound healing under the influence of
enhanced engrafted EPCs in Lnk-/- mice
Our previous studies showed that in vivo genetic
targeting of Lnk enhances osteogenesis, neovasculari-
zation, and astrogliosis in mouse models of some dis-
eases [13, 18, 19]. To test whether the lack of the
Lnk gene affects wound healing in an in vivo murine
excisional wound model, we generated an excisional
wound in Lnk+/+ and Lnk-/- mice (Fig. 1a). Wound
closure was significantly enhanced in Lnk-/- mice
compared with wild-type mice (Fig. 1b). Histological
analysis by H&E staining showed that the gap of
wounds was significantly decreased in Lnk-/- mice
compared with wild-type mice (Fig. 1c and d). To
confirm that the EPC population is involved in
wound healing, after digestion of wound tissues, iso-
lated cells were characterized by flow cytometric ana-
lysis for Sca-1+/c-Kit+ markers and Flk-1+/CD34+
markers, which represent typical EPC population
markers (Fig. 1e and f ). FACS analysis indicated that
Sca-1+/c-Kit+ and Flk-1+/CD34+ cells were signifi-
cantly more prevalent in wound tissues of Lnk-/- mice
than in wound tissues of wild-type mice (Fig. 1g and h).
These results suggest that the specific disruption of the
Lnk gene promotes wound repair in an excisional wound
model through the recruitment of EPC populations to is-
chemic sites.
Fig. 1 Lnk deficiency improves wound repair in a murine model of an excisional wound. a Photographs of the wound were captured on days 0–10
after administration of an excisional wound to wild-type (WT) and Lnk-deficient mice. b This graph shows the proportion of the wound area at the
indicated time points post wounding. Values are mean ± SEM; *p < 0.05 and **p < 0.01 compared to the wound area in Lnk-deficient mice. c An H&E-
stained section of a skin wound in WT and Lnk-deficient mice at the indicated time points post wounding. d The graph shows the proportion of the
wound gap at the indicated time points post wounding. Values are mean ± SEM; **p < 0.01 compared to the wound gap in WT mice. e Wound sites
were analyzed to identify Sca-1/c-Kit-positive EPCs by FACS analysis. f Wound sites were analyzed to determine Flk-1/CD34-positive EPCs by FACS
analysis. g and h The graph shows the percentage of Sca-1/c-Kit-positive cells (g) and Flk-1/CD34-positive cells (h) at wound sites of WT and Lnk-
deficient mice. Values are mean ± SEM; **p < 0.01 compared to WT mice
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The enhanced vasculogenic potential of Lnk-deficient EPCs
To evaluate EPC surface markers, we isolated BM-
derived EPCs from Lnk+/+ and Lnk-/- mice. Interestingly,
typical murine EPC markers including Sca-1, c-Kit,
CD34, and Flk-1, were significantly upregulated in Lnk-
deficient EPCs in comparison with wild-type EPCs
(Fig. 2a and b). To further assess EPC bioactivities, we
confirmed cell proliferation, tubule-like formation, and
migration capacity. Proliferation was significantly in-
creased in Lnk-deficient EPCs, compared with wild-type
EPCs in both a serum-free medium and complete
medium (Fig. 2c). The Matrigel tube formation assay re-
vealed that Lnk-deficient EPCs have higher tube forma-
tion capacity than wild-type EPCs do (Fig. 2d and e).
Migration capacity was also significantly increased in
Lnk-deficient EPCs compared with wild-type EPCs in
response to vascular endothelial growth factor (VEGF)
and stromal cell-derived factor 1 (SDF-1) (Fig. 2f and g).
These findings indicated that the lack of the Lnk gene in
a BM niche gives rise to functional EPCs because of ex-
pression of typical EPC surface markers and because of
enhanced EPC bioactivities, including cell proliferation,
cell migration, and tubule-like formation.
Improved wound repair after subcutaneous injection of
Lnk-deficient EPCs
To explore the effects of Lnk-deficient EPCs on wound
repair in a murine excisional wound model, after cre-
ation of excisional wounds in wild-type mice, we sub-
cutaneously injected wild-type or Lnk-deficient EPCs
into the wound border area (Fig. 3a). The wound area
was significantly reduced by injection of Lnk-deficient
Fig. 2 Evaluation of characteristics and functionalities of EPCs. a After isolation of EPCs from wild-type (WT) and Lnk-deficient mice, EPC surface
markers, including Sca-1, c-Kit, CD34, and Flk-1, were analyzed on a FACS. b The graph shows the percentage of EPCs with surface markers among
WT and Lnk-deficient EPCs. Values are mean ± SEM; **p < 0.01 compared to WT EPCs. c Proliferation of EPCs was evaluated in serum-free or
complete media by a 5-bromo-2′-deoxyuridine (BrdU) assay. Values are mean ± SEM; **p < 0.01 compared to proliferation of WT EPC in a serum-
free medium; ##p < 0.01 compared to WT EPCs. d Tube formation capacity of HUVECs, WT EPCs, and Lnk-deficient EPCs was determined by a
Matrigel tube formation assay (magnification × 40). e The graph shows the number of capillaries among HUVECs, WT EPCs, and Lnk-deficient EPCs.
Values are mean ± SEM; **p < 0.01 compared to HUVECs and ##p < 0.01 compared to WT EPCs. f Migration capacity was assessed by a wound
scratch assay (magnification × 40). g The graph shows the number of migrating cells among WT EPCs and Lnk-deficient EPCs in response to VEGF
or SDF-1α. Values are mean ± SEM; **p < 0.01 compared to WT mice
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EPCs, as compared with the area after injection of PBS
or wild-type EPCs (Fig. 3b). On postoperative day 10,
neovascularization was assessed by immunofluorescence
staining for CD31 (Fig. 3c). This staining indicated that
neovascularization was significantly enhanced by injec-
tion of Lnk-deficient EPCs as compared with injection
of wild-type EPCs (Fig. 3g). To verify incorporation into
the vessels, cell proliferation, and survival of the trans-
planted EPCs, after membranes of EPCs were labeled
with PKH26, the cells were transplanted into wound
border sites. Three days after the transplant of EPCs, in-
corporation into vessels as well as cell proliferation and
apoptosis were assessed by immunofluorescent staining
for PKH26/CD31 (incorporation; Fig. 3d), PKH/PCNA
(proliferation; Fig. 3e), and PKH26/cleaved caspase 3
(apoptosis; Fig. 3f ). Incorporation into vessels and prolif-
eration were significantly increased in transplanted Lnk-
deficient EPCs, compared with wild-type EPCs (Fig. 3h
and i). Apoptosis was significantly decreased in trans-
planted Lnk-deficient EPCs compared with wild-type
Fig. 3 Assessment of functional recovery in a wound excision model after subcutaneous injection with EPCs. a After administration of an excisional
wound to wild-type (WT) mice, we subcutaneously transplanted PBS, WT EPCs, and Lnk-deficient EPCs into wound sites. b The graph shows the
proportion of the wound area at the indicated time points post wounding. Values are mean ± SEM; **p < 0.01 compared to injection with PBS and
##p < 0.01 compared to injection with WT EPCs. c On postoperative day 10, capillary formation was evaluated by immunofluorescence staining for
CD31 (green). Nuclei were stained with DAPI (blue). Scale bar = 50 μm. d After PKH26 dye (red)-stained EPCs were subcutaneously injected into wound
sites, incorporation of the transplanted EPCs into vessels was assessed by immunofluorescent staining for CD31 (green) on postoperative
day 3. e Proliferation of transplanted EPCs was confirmed by immunofluorescent staining for PCNA (green) on postoperative day 3. f Apoptosis among
transplanted EPCs was detected by immunofluorescent staining for cleaved caspase 3 (green) on postoperative day 3. g The graph shows the number
of CD31-positive cells. Values are mean ± SEM; **p < 0.01 compared to injection with WT EPCs. h The graph shows the number of PKH26/CD31-positive
cells. Values are mean ± SEM; **p < 0.01 vs. injection with WT EPCs. i The graph shows the number of PKH26/PCNA-positive cells. Values are
mean ± SEM; **p < 0.01 compared to injection with WT EPCs. j The graph shows the number of PKH26/cleaved caspase 3-positive cells.
Values are mean ± SEM; **p < 0.01 compared to injection with WT EPCs
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EPCs (Fig. 3j). These results suggest that Lnk-deficient
EPCs improve wound healing through enhancement of
neovascularization and via augmentation of incorpor-
ation into vessels, proliferation, and survival of the trans-
planted cells.
Decreased numbers of inflammatory cells among
engrafted Lnk-deficient EPCs
In the inflammatory phase (1–3 days after injury), leuko-
cytes are recruited to the wound site to remove cell deb-
ris and pathogens. On the other hand, persistent
presence of inflammatory cells at wound sites leads to
delayed wound healing and to cell death [20]. To con-
firm the inhibitory effect of Lnk-deficient EPCs on the
recruitment of inflammatory cells to wound sites 3 days
after injury, we subcutaneously injected wild-type and
Lnk-deficient EPCs and then assessed the recruitment of
inflammatory cells to wound sites on postoperative day
7. The percentage of CD3 and CD8 double-positive cells,
which are a cytotoxic T cell population, was significantly
decreased after injection of Lnk-deficient EPCs as com-
pared with injection of wild-type EPCs (Fig. 4a and b).
In addition, the number of cells positive for CD11b (a
macrophage marker) and CD45 (a neutrophil marker)
was significantly decreased after injection of Lnk-deficient
EPCs on postoperative day 7, as compared with that after
injection of wild-type EPCs (Fig. 4c and d). These data
suggested that a transplant of Lnk-deficient EPCs sup-
presses the recruitment of inflammatory cells in the prolif-
eration or remodeling phase.
Activated fibroblasts among engrafted Lnk-deficient EPCs
In the remodeling phase, activated fibroblasts play an
important role in tissue remodeling and wound repair
[3]. To determine whether Lnk-deficient EPCs activate
fibroblasts and induce differentiation of fibroblasts into
myofibroblasts, we assessed proliferation of fibroblasts
in vitro and differentiation of fibroblasts into myofibro-
blasts in vivo. After addition of an EPC-conditioned
medium to fibroblasts, dermal-fibroblast proliferation
was confirmed. Proliferation of fibroblasts was signifi-
cantly facilitated by conditioned media from Lnk-
deficient EPCs in contrast to wild-type EPC conditioned
media (Fig. 5a). Seven days after injection of EPCs into
the wound area of wild-type mice, myofibroblast differ-
entiation was assessed by immunofluorescent staining
for alpha-smooth muscle actin (α-SMA) and vimentin
(Fig. 5b). The number of myofibroblasts that were α-
SMA and vimentin double-positive was significantly
increased by injection with Lnk-deficient EPCs, as
Fig. 4 A transplant of Lnk-deficient EPCs suppresses the recruitment of inflammatory cells. After injection of wild-type (WT) and Lnk-deficient
EPCs into wound sites, wound tissues were analyzed to determine the recruitment of cytotoxic T cells (CD3- and CD8-positive cells),
macrophages (CD11b-positive cells), and neutrophils (CD45-positive cells) on postoperative days 3 and 7. a The recruitment of cytotoxic
T cells in wound tissues was assessed by FACS analysis. b The percentage of CD3/CD8 double-positive cells on postoperative days 3 and 7. Values
are mean ± SEM; **p < 0.01 compared to postoperative day 3, respectively, and ##p < 0.01 compared to injection with WT EPCs. c The recruitment of
macrophages and neutrophils to wound tissues was assessed by FACS analysis. d The percentage of CD11b- and CD45-positive cells on postoperative
days 3 and 7. Values are mean ± SEM; **p < 0.01 compared to postoperative day 3, respectively, #p < 0.05 and ##p < 0.01 compared to injection with
WT EPCs
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compared with injection of wild-type EPCs (Fig. 5c).
Masson’s trichrome staining indicated that injection
of Lnk-deficient EPCs significantly decreased the fibrotic
area on postoperative days 7 and 10 in comparison with
the injection of wild-type EPCs (Fig. 5d and e). These re-
sults suggest that Lnk-deficient EPCs promote wound
healing through activation of fibroblasts.
Wound repair is improved by the engrafted Lnk-deficient
EPCs in a model of a type I diabetes excisional wound
To test whether a transplant of Lnk-deficient EPCs im-
proves wound healing in a mouse model of type 1 dia-
betes, we created a murine model of STZ-induced
diabetes (Fig. 6a and b). After administering an exci-
sional wound to mice with STZ-induced diabetes, wild-
type or Lnk-deficient EPCs were transplanted into the
wound border area (Fig. 6c). The wound healing area
was significantly increased in the “Lnk-deficient EPC in-
jection” group compared with the other groups (Fig. 6d).
These results indicated that Lnk-deficient EPCs im-
proved wound healing in the model of type 1 diabetes.
Discussion
The wound repair process is a complex and well-
coordinated regenerative response that involves a cross-
talk among several types of cells, growth factors,
cytokines, ECM, and soluble factors. Various risk factors,
however, such as diabetes, hypoxia, ischemia, and infec-
tion, lead to dysfunction of various types of cells and to
production of soluble mediators, resulting in wound
underhealing or overhealing. Recently, several studies
showed that local or systemic administration of stem or
progenitor cells, such as mesenchymal stem cells (MSCs)
and EPCs, enhances wound repair and angiogenesis
[10, 21]. In particular, these studies revealed that the
use of genetically engineered cell populations could
increase the therapeutic efficacy, because the harsh
pathological environment, including hypoxia, drastic-
ally affects the survival rate of the unmodified trans-
planted cells. In the present study, the major findings
are as follows: (1) Lnk deficiency in EPCs enhances the ex-
pression of functional EPC markers and bioactivities such
as proliferation, migration, and capacity for tubule-like
formation; (2) a transplant of Lnk-deficient EPCs en-
hances wound repair via inhibition of recruitment of leu-
kocytes in the inflammatory phase and by activation of
myofibroblasts in the tissue-remodeling phase; (3) admin-
istration of Lnk-deficient EPCs improves wound healing
in mice with STZ-induced diabetes.
Lnk is an adaptor protein that mediates protein–protein
and protein–phospholipid interactions without an intrin-
sic enzymatic function [22, 23]. Lnk, as a key molecular
Fig. 5 The cross-talk of EPCs with fibroblasts in vitro and in vivo. a After isolation of skin fibroblasts from wild-type mice, these cells were cultured
in a WT EPC conditioned medium (CM) or Lnk-deficient EPC CM for 24 h. Proliferation of fibroblasts was assessed by the BrdU assay. Values are
mean ± SEM; **p < 0.01 compared to control, and ##p < 0.01 compared to WT EPC-CM. b After subcutaneous injection with EPCs into the wound
area, the presence of myofibroblasts (α-SMA and vimentin double-positive cells) at wound sites was evaluated by immunofluorescent staining for
α-SMA (red) and vimentin (green) on postoperative day 7. Nuclei were stained with DAPI (blue). Scale bar = 50 μm. c The graph shows the number
of α-SMA and vimentin double-positive cells at wound sites on postoperative day 7. Values are mean ± SEM; **p < 0.01 vs. injection with WT EPCs.
d Masson’s trichrome staining was performed to determine the fibrotic area on postoperative days 7 and 10. e The graph shows the relative fibrotic
area 7 and 10 days after EPC injection. Values are mean ± SEM; **p < 0.01 compared to injection with WT EPC on postoperative day 7, ##p < 0.01
compared to injection with Lnk-deficient EPCs on postoperative day 7, and $$p < 0.01 compared to injection with WT EPCs on postoperative day 10
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target, augments the function of EPCs and neovasculariza-
tion [12]. Our findings indicated that wound repair was
significantly enhanced in Lnk-deficient mice as compared
with wild-type mice. However, wound repair is a complex
biological process that requires several cell types [1, 2],
and the Lnk adaptor protein affects various of cell types,
including hematopoietic stem cells [24], T cells [25], mac-
rophages [26], EPCs [13, 14], and endothelial cells [27].
Therefore, to focus on one of the populations involved in
the wound-healing process, we performed flow cytometry
in the wound tissues to search for the recruitment of a
specific cell population, and demonstrated that Lnk defi-
ciency in mice specifically increased the recruitment of
the EPC population to the injury sites. In a model of bone
fracture, Lnk-deficient mice show improved osteogenesis
because of enhanced angiogenesis through the recruit-
ment of EPCs to the prefracture zone [28]. Our data also
revealed that the EPC bioactivities, including proliferation,
migration, and tube formation capacity were significantly
higher in Lnk-deficient EPCs than in wild-type EPCs. Our
previous studies showed that Lnk deficiency in mice
promotes EPC kinetics and neovascularization in response
to angiogenic cytokines, such as SCF, VEGF, and SDF-1
[13]. In addition, Lnk-deficient EPCs increase the clono-
genic proliferation via activation of the JAK-STAT3 signal
pathway [14]. These findings strongly support the notion
that Lnk deficiency in mice promotes wound repair
through the recruitment of EPCs and improves EPC cellu-
lar bioactivities, which are initiating steps of vascular re-
pair, which is tightly regulated by the Lnk adaptor protein
for cellular homeostasis.
EPCs, as key progenitors of endothelial cells, partici-
pate in neovascularization and tissue repair. After ad-
ministration of a cutaneous wound to mice, BM-derived
EPC mobilization is increased via the SDF-1α/CXCR4
axis [29]. A human cord blood-derived EPC transplant
accelerates wound closure in nude mice with STZ-
induced diabetes by stimulation of proliferation of kera-
tinocytes and fibroblasts [30]. Our results show that
wound closure is significantly better after an EPC trans-
plant than after PBS injection. Moreover, the transplant
of Lnk-deficient EPCs significantly enhanced wound
Fig. 6 Effects of a Lnk-deficient EPC transplant on wound repair in mice with STZ-induced diabetes. a To establish a mouse model of type 1 diabetes
mellitus (T1DM), blood glucose was assessed after a streptozotocin (STZ) injection. b H&E staining of a tissue slice shows necrosis of β-cells in the
pancreas (magnification × 40). c After injection of EPCs into an excisional wound of normal mice or mice with STZ-induced diabetes, photographs of
the wound were captured on days 0–10. d The graph shows the proportion of the wound area at the indicated time points post wounding. Values
are mean ± SEM; *p < 0.05 and **p < 0.01 compared to injection with PBS in mice with STZ-induced diabetes, #p < 0.05 and ##p < 0.01 compared to
injection of WT EPCs into mice with STZ-induced diabetes
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healing through the improvement of transplanted-cell
proliferation and survival as well as neovascularization,
as compared with a transplant of wild-type EPCs. In a
hindlimb ischemia model, our previous report clearly
showed that a transplant of Lnk-deficient EPC enhances
proliferation and survival as well as neovascularization
through regulation of the JAK2/STAT3 signaling path-
way [14]. In a mouse model of spinal cord injury, we
also reported that Lnk-deficient, c-Kit-positive, Sca-1-
positive, and lineage marker-negative cell populations
(which are a core source of EPCs) enhance angiogenesis,
astrogliosis, and functional recovery [19]. These previous
reports support our present findings that a transplant of
Lnk-deficient EPCs promotes wound healing through
enhancement of neovascularization.
In the inflammatory phase, a healthy inflammatory re-
action is involved in wound healing through the removal
of necrotic tissues, debris, and pathogen contaminants,
as well as via recruiting and activating fibroblasts. Leu-
kocytes, including macrophages and neutrophils, appear
in the wound at 1–3 days after injury and continue the
process of phagocytosis [31]. Nonetheless, inflammation
under pathological conditions such as in a chronic dis-
ease leads to delayed healing and promotes inflamma-
tion. In the proliferation phase (4–14 days after injury),
overactivated immune cells induce scar formation and fi-
brosis [31, 32]. The possible reason for the continued
presence of inflammatory cells is their persistent recruit-
ment and activation due to tissue injury from enhanced
mechanical pressure, pathogens, leukocyte trapping, and
ischemic injury [20]. Cell death and tissue necrosis also
cause inflammation [33]. In addition, inflammation and
oxidative stress affect EPC mobilization. Our data show
that neither wild-type nor Lnk-deficient EPCs affected
immune cell recruitment in the inflammatory phase
(postoperative day 3), whereas transplantation of Lnk-
deficient EPCs significantly decreased the recruitment of
macrophages and neutrophils after postoperative day 7
as compared with transplantation of wild-type EPCs.
Human gingiva-derived MSCs accelerate wound healing
by eliciting M2 polarization in macrophages [34]. In cor-
neal injury, MSCs promote corneal wound healing by
their anti-inflammatory action, including secretion of IL-
10, IL-6, and transforming growth factor beta 1 (TGF-
β1) [35]. IL-10-deficient EPCs show decreased survival
and function at ischemic sites [36]. These results suggest
that Lnk-deficient EPCs have an anti-inflammatory effect
after a transplant in an excisional wound. Additional
studies will obviously be necessary to further elucidate
the complex role of Lnk-deficient EPCs in secretion of
anti-inflammatory paracrine factors and their functions
during dermal wound healing.
In the remodeling phase, activated fibroblasts, which
have a myofibroblast phenotype, perform the ECM
remodeling. Fibroblast-to-myofibroblast differentiation
represents a pivotal process during wound healing and
tissue repair, because the high contractile force gener-
ated by myofibroblasts is effective for physiological tis-
sue remodeling [32, 37]. Although the mechanism of
skin contraction is different between mice and humans,
reduced fibroblast proliferation leads to a strong delay in
wound closure [38]. To evaluate the potential preclinical
and clinical application of Lnk-deficient EPCs as a cell-
based therapeutic, we focused on the bioactivity of fibro-
blasts through transplantation of EPCs [31, 37, 39]. The
results of this study indicate that Lnk-deficient EPCs ac-
tivate fibroblasts in vitro and induce the differentiation
of fibroblasts into myofibroblasts in vivo. In particular,
the fibrotic area was significantly decreased in mice
transplanted with Lnk-deficient EPCs compared with
that of mice transplanted with wild-type EPCs. Myofi-
broblasts perform a key function in wound healing and
in contractile forces [39]. Trophic activity of MSCs in-
creases skin wound closure by activation of dermal fi-
broblasts [40]. Coculture of fibroblasts with EPCs
improves functional recovery after a myocardial infarc-
tion [41]. Engraftment of EPCs into an excisional wound
model in diabetic mice augments wound repair via fibro-
blast proliferation [30]. These findings indicate that Lnk-
deficient EPCs may be engaged in a cross-talk with fi-
broblasts for wound healing, but the precise mechanism
of action of Lnk-mediated signaling cascades and the dif-
ference in skin contraction between mice and humans
should be further investigated to support their preclin-
ical and clinical application.
Finally, we assessed the effect of a transplant of Lnk-
deficient EPCs on wound repair in mice with STZ-
induced diabetes to confirm the beneficial effects of
Lnk-deficient EPCs in a chronic disease. Our results re-
vealed that wound repair is significantly better after a
transplant of Lnk-deficient EPCs as compared with that
in other groups. This study has some limitations to com-
prehensively determine the effect of Lnk-deficient EPCs
in chronic diseases in general. In particular, we estab-
lished a type 1 diabetes mouse model for wound healing;
however, a type 2 diabetes model might be a more ap-
propriate chronic disease model. To reveal the availabil-
ity and possibility of EPCs for cell-based therapy in
diabetes, we first confirmed the effect of Lnk-deficient
EPCs in a type 1 diabetes model. In addition, the
wound-healing mechanism might be different between
mice and humans, since skin contraction plays a greater
role in the rodent wound-healing mechanism than in that
of humans. Therefore, in future studies, the effect of Lnk
gene silencing will be investigated in type 1 and 2 diabetic
models, and the precise role of Lnk in EPC-mediated
wound healing will be evaluated in the chronic disease
condition to support preclinical and clinical application.
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Conclusions
Although the effects of Lnk deficiency in EPCs should
be further studied in chronic disease models, our find-
ings imply that Lnk-deficient EPCs might be a promising
cell source for stem or progenitor cell-based treatments
of chronic diseases. Taken together, this study involving
murine disease models revealed that specific disruption
of Lnk promotes EPC bioactivities such as proliferation,
migration, and tube formation in vivo and in vitro. A
transplant of Lnk-deficient EPCs promotes wound repair
through enhancement of angiogenesis, inhibition of
inflammation, and activation of myofibroblasts. In
addition, our results showed the possibility of thera-
peutic application of Lnk-mutated EPCs in a diabetic
wound model and give some clues to the precise regula-
tion of the Lnk gene. Thus, specific targeting of Lnk-
mediated signaling might be a promising strategy for the
development of cell-based therapeutics.
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